Comparative Pharmacology
Head-to-head clinical analysis: ALBENZA versus ANTEPAR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALBENZA versus ANTEPAR.
ALBENZA vs ANTEPAR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Albendazole is a benzimidazole carbamate that inhibits tubulin polymerization by binding to the colchicine site of β-tubulin, disrupting microtubule formation. This leads to impaired uptake of glucose and depletion of glycogen stores, resulting in immobilization and death of susceptible helminths.
Piperazine, the active ingredient, causes paralysis of the parasite by blocking acetylcholine at the neuromuscular junction and altering muscle membrane ion permeability.
400 mg orally twice daily for 60 days for neurocysticercosis; 400 mg orally once daily for 3 days for pinworm; 400 mg orally once daily for 3 days for hookworm, roundworm, whipworm; 400 mg orally twice daily for 3 days for tapeworms; 400 mg orally twice daily for 7 days for giardiasis.
Adult: 50-75 mg/kg/day orally in 3 divided doses for 3 days; maximum 3 g/day.
None Documented
None Documented
Terminal elimination half-life of albendazole sulfoxide (active metabolite) is 8-12 hours; albendazole itself has a very short half-life (<1 hour) due to extensive first-pass metabolism.
Terminal elimination half-life is approximately 3-4 hours in patients with normal renal function; may be prolonged in renal impairment.
Primarily biliary/fecal (less than 2% renal as unchanged drug and metabolites; most eliminated via bile into feces as metabolites).
Renal elimination of unchanged drug and metabolites accounts for approximately 70-80%, with the remainder excreted in feces via biliary elimination.
Category C
Category C
Anthelmintic
Anthelmintic